Melatonin is not broadly harmful for people with diabetes, but its effects on blood sugar depend heavily on when you take it and, to some degree, on your genetics. The relationship between melatonin and glucose is genuinely paradoxical: the hormone directly dampens insulin release in the short term, yet long-term supplementation tends to improve blood sugar markers in clinical trials. Researchers have spent over a decade trying to untangle this contradiction, and the emerging answer centers on timing.
Melatonin Directly Inhibits Insulin Release
Your pancreatic beta cells, the ones responsible for producing insulin, have melatonin receptors on their surface. When melatonin binds to those receptors, it dials down insulin secretion. This has been confirmed across cell studies and animal models, and it is not subtle: in rats, higher melatonin levels reliably correspond to lower insulin output, and vice versa.1PubMed Central. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon This inverse relationship is the basis for the concern that melatonin could worsen blood sugar control in people who already have trouble producing or responding to insulin.
But there is a crucial piece of context that often gets lost. Your body naturally produces melatonin at night, when you are asleep and not eating. The insulin-suppressing effect is part of normal physiology. Your pancreas does not need to pump out insulin while you are sleeping and fasting. Melatonin essentially tells the beta cells to stand down during the hours when their services are not required. The trouble starts when melatonin levels are high at the same time you are eating or when your body is trying to process a glucose load.
Why Timing Changes Everything
This is the crux of the melatonin-diabetes debate. Researchers have proposed that much of the confusion in the scientific literature comes from ignoring the dimension of time. When elevated melatonin overlaps with a meal or glucose challenge, blood sugar rises more than it normally would because insulin release is being suppressed at exactly the moment it is needed. When melatonin is elevated during its natural window, with no food coming in, that same suppression is harmless or even beneficial.2PubMed Central. Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy
A study in healthy young men illustrates this nicely. When melatonin was given before a late evening meal, it actually improved glucose tolerance and insulin sensitivity and reduced post-meal blood fats.3PubMed Central. The effect of melatonin on glucose tolerance, insulin sensitivity and lipid profiles after a late evening meal in healthy young males That might sound contradictory given that melatonin suppresses insulin, but it makes sense if the broader metabolic signaling, including how tissues respond to insulin and how the liver handles glucose, benefits from having melatonin in the picture during a period of circadian misalignment. The researchers specifically noted the implications for shift workers, who often eat at times when their melatonin rhythm is disrupted.
The practical upshot for someone with diabetes: taking melatonin at bedtime and then going to sleep is consistent with normal physiology. Taking it and then eating a snack or having it still active in your bloodstream when you eat breakfast could temporarily impair your glucose tolerance. Most over-the-counter melatonin supplements are fast-acting and clear within a few hours, so a standard dose taken 30 to 60 minutes before a normal bedtime is unlikely to cause a glucose problem at breakfast. But if you are someone who takes melatonin and then stays up eating, the picture changes.
A Genetic Factor That Raises the Stakes for Some People
Not everyone’s beta cells respond to melatonin the same way. A common genetic variant in the gene for the melatonin receptor (called MTNR1B, specifically the SNP rs10830963) has been consistently linked to higher fasting glucose levels and increased risk of type 2 diabetes. Roughly a third of people of European ancestry carry at least one copy of this risk variant, so it is not rare.
What happens in carriers of this variant is that their pancreatic beta cells produce more melatonin receptors than average. More receptors means a stronger response when melatonin shows up. The result is a more pronounced suppression of insulin release, leading to higher glucose levels after melatonin exposure.4PubMed. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes In a human recall-by-genotype study, people with the risk variant who were given melatonin had a bigger drop in insulin secretion and a bigger spike in blood sugar compared to people without it.4PubMed. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes
The original genome-wide association study that identified this variant found that the risk genotype was linked to impaired early insulin response to both oral and intravenous glucose, plus a faster decline in insulin secretion over time. People with type 2 diabetes and nondiabetic risk-allele carriers both showed increased receptor expression in their islets.5PubMed Central. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion
Here is where it gets interesting in terms of practical life choices. A controlled laboratory study found that carriers of this risk variant produce melatonin for longer into the morning. Their melatonin does not shut off as early after waking. People with early wake times who carry the variant face the most pronounced diabetes risk, because they are awake and potentially eating while melatonin is still elevated. Carriers with later wake times did not show nearly as much increased risk, because their extended melatonin window gets masked by sleeping in.6PubMed Central. Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology If you carry this variant (and most people do not know whether they do), early-morning eating while supplemental melatonin is still in your system could be a genuine concern.
What Clinical Trials Show About Long-Term Use
Despite the acute insulin-suppressing effect, clinical trial data on melatonin supplementation in people with type 2 diabetes paints a mostly positive picture. A systematic review and meta-analysis of randomized trials found that melatonin supplementation significantly reduced fasting blood glucose, hemoglobin A1c (a marker of average blood sugar over two to three months), and insulin resistance.7PubMed. Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials A more recent meta-analysis confirmed a statistically significant reduction in A1c with melatonin compared to placebo, though the researchers cautioned that the effect was borderline and the confidence interval came close to showing no benefit.8PubMed Central. The effect of melatonin supplementation on glycemic control in patients with type 2 diabetes
So the evidence suggests a modest benefit on blood sugar control, not harm. These are small effects and the trials have been relatively short, so no one is proposing melatonin as a standalone diabetes treatment. But the direction of the effect is reassuring for someone with diabetes who needs melatonin for sleep. The trials typically used doses in the range common in over-the-counter supplements, taken at bedtime.
How do you square this with the insulin-suppressing mechanism? Probably because the nighttime insulin suppression is metabolically appropriate and because melatonin’s broader effects, on circadian rhythm regulation, oxidative stress, and inflammation, have their own benefits for metabolic health over time. The short-term snapshot of “melatonin makes insulin go down” does not capture everything the hormone does across a full 24-hour cycle.
Low Melatonin Is Itself a Diabetes Risk Factor
Flipping the question around reveals an important finding: people who naturally produce less melatonin are at higher risk for type 2 diabetes, not lower. A large prospective study published in JAMA measured overnight melatonin output in women and followed them over time. Women with higher melatonin secretion had better insulin sensitivity and lower insulin resistance. Lower melatonin secretion was associated with a higher incidence of type 2 diabetes.9PubMed Central. Melatonin secretion and the incidence of type 2 diabetes
This lines up with the observation that conditions causing low melatonin, aging, shift work, sleeping in lit environments, are all associated with insulin resistance, glucose intolerance, and metabolic disruption.10PubMed Central. Melatonin, energy metabolism, and obesity: a review The hormone appears to play a role in keeping the body’s internal clocks synchronized, and when those clocks drift, metabolic problems follow. By that logic, supplementing melatonin in people whose production is low could be correcting a deficiency rather than introducing a risk.
Melatonin production declines with age, which tracks with the rising prevalence of type 2 diabetes in older populations. Some researchers have argued that by supporting strong circadian rhythms, melatonin may help prevent or delay diabetes, even though the acute effect on beta cells runs in the opposite direction.11PubMed Central. Melatonin and the pathologies of weakened or dysregulated circadian oscillators
Protective Effects on Beta Cells
Beyond its signaling role, melatonin acts as an antioxidant, and this has specific relevance for diabetes. High blood sugar damages beta cells through oxidative stress and inflammation over time, which is part of why type 2 diabetes tends to get progressively worse. In laboratory studies, melatonin reduced beta cell death and aging caused by chronically high glucose and fat exposure, boosted the cells’ own antioxidant defenses, and improved their ability to secrete insulin in response to glucose.12PubMed Central. Melatonin protects INS-1 pancreatic β-cells from apoptosis and senescence induced by glucotoxicity and glucolipotoxicity
In diabetic rats, melatonin treatment protected beta cells under severe inflammation and led to visible regeneration of the islets of Langerhans, the clusters of cells in the pancreas that produce insulin.13Saudi Journal of Biological Sciences. Melatonin relieves diabetic complications and regenerates pancreatic beta cells by the reduction in NF-kB expression in streptozotocin induced diabetic rats These are animal and cell studies, so the effect in humans is not proven to the same degree, but the pattern is consistent: melatonin seems to shield the very cells that diabetes gradually destroys.
Melatonin and Metformin Together
A common practical question for people with type 2 diabetes is whether melatonin interacts with their medications. Metformin is the most widely prescribed diabetes drug, so the combination has received some attention. In animal studies, combining melatonin with metformin produced synergistic benefits: better insulin sensitivity, improved circadian activity rhythms, reduced fat accumulation, and less beta cell failure than either treatment alone.14PubMed Central. Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats
In high-fat-fed rats, melatonin alone improved insulin sensitivity to the same degree as metformin, and the combination pushed insulin sensitivity even further while also reducing food intake more than metformin alone.15PubMed Central. Melatonin potentiates the effects of metformin on glucose metabolism and food intake in high-fat-fed rats These are rodent studies, so dosing does not translate directly to humans, but the absence of negative interactions and the presence of apparent synergy is encouraging. A clinical trial of prolonged-release melatonin in people with diabetes and insomnia allowed participants to continue all their existing medications, including diabetes drugs, throughout the study without reported adverse metabolic interactions.16PubMed Central. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study
Gut Bacteria and Blood Sugar
An emerging line of research connects melatonin’s metabolic effects to changes in the gut microbiome. In a study using diabetic mice, melatonin supplementation over 12 weeks reshaped the gut microbial community and reduced fecal levels of several short-chain fatty acids. The mice showed improved insulin sensitivity and lower fasting blood glucose, and statistical analysis tied those improvements to the changes in gut bacteria and short-chain fatty acid profiles.17PubMed Central. Melatonin improved glucose homeostasis is associated with the reprogrammed gut microbiota and reduced fecal levels of short-chain fatty acids in db/db mice The mice also drank less water and urinated less, signs that their diabetic symptoms were improving.
This is early-stage research in animals, and the gut microbiome is fiendishly complex to study. But it opens up the possibility that some of melatonin’s metabolic benefits work through indirect routes that have nothing to do with the insulin-suppressing receptor mechanism on beta cells. The gut pathway would also help explain why chronic supplementation has different effects from a single dose.
Type 1 Diabetes Considerations
Most of the melatonin-diabetes research focuses on type 2 diabetes, but there is some data relevant to type 1. In a mouse model of autoimmune diabetes, melatonin treatment prolonged the survival of transplanted islet grafts by suppressing the immune attack that destroys beta cells. The mechanism appeared to involve a shift away from the inflammatory immune cells that drive the autoimmune response, partly through an increase in the immunosuppressive signaling molecule IL-10.18PubMed. Melatonin prolongs islet graft survival in diabetic NOD mice
This is mouse work, so it is a long way from a clinical recommendation. But the immune-modulating properties of melatonin are potentially relevant to type 1 diabetes in a way that does not apply to type 2. People with type 1 diabetes who take melatonin for sleep should be aware that the existing animal evidence does not suggest harm and, if anything, points toward a protective immune effect.
Gestational Diabetes
Pregnancy introduces its own set of hormonal changes, and gestational diabetes is a growing concern globally. Research has found that women who develop gestational diabetes tend to have lower melatonin production and disrupted circadian melatonin rhythms compared to women with normal pregnancies.19MOJ Current Research & Reviews. The role of melatonin in the development of gestational diabetes Low melatonin appears to be part of the underlying risk profile rather than a consequence of the condition.
Whether supplementing melatonin during pregnancy could prevent gestational diabetes has not been established in clinical trials, and melatonin supplementation during pregnancy carries its own set of safety unknowns. But the association between low melatonin and gestational diabetes risk fits the broader pattern: the body seems to need adequate melatonin for normal glucose regulation, and a deficit creates vulnerability.
Practical Guidance for People with Diabetes
If you have diabetes and are considering melatonin for sleep, the current evidence does not suggest you need to avoid it. The clinical trial data shows either neutral or modestly beneficial effects on blood sugar markers when melatonin is taken at bedtime. A few practical points are worth keeping in mind:
- Take it at bedtime: Align supplementation with the time your body would naturally produce melatonin. The conflict with insulin matters when melatonin and food overlap, so take it when you are done eating for the night.
- Do not eat after taking it: A late-night snack while melatonin is active in your bloodstream could impair your glucose response to that food.
- Start with a low dose: Most research uses doses in the 2 to 5 mg range. Higher doses do not produce proportionally better sleep and may prolong the window of elevated melatonin into the morning.
- Monitor your morning glucose: If you notice your fasting blood sugar is higher after starting melatonin, it could be a sign that the supplement is still active when you eat breakfast. Shifting your dose earlier in the evening or reducing it may help.
- Tell your doctor: Especially if you are on insulin or medications that affect blood sugar, your healthcare provider should know about any supplement you add.
The Genetic Question You Cannot Easily Answer
The MTNR1B risk variant adds a layer of individual variability that standard medical advice does not yet account for. Consumer genetic testing services do genotype this variant, so it is technically possible to look up your rs10830963 status if you have been genotyped. But the clinical significance of knowing this is still unclear. Carriers of the risk allele are not told to avoid melatonin by any medical guideline, partly because the long-term trial data has not been broken down by genotype in a way that would support different recommendations.
What the genetics research does suggest is that if you carry the risk variant and you are an early riser, you may want to be especially careful about the timing of melatonin relative to your first meal. The extended melatonin duration associated with this variant means your body is still producing its own melatonin later into the morning. Adding supplemental melatonin on top of that could widen the window of overlap with breakfast even further. For most people without genetic testing data, the simpler advice holds: take melatonin at a reasonable bedtime, do not eat after taking it, and check whether your morning numbers change.